This article described the new forms of glaucoma treatments that will be issued by the biggest pharmaceutical companies such as Allergan Inc. and Pfizer. Glaucoma is an eye disease that affects more than 4 million Americans. Seeing that there is no known cure for the disease, these pharmaceutical companies are providing patients with relief from the negative symptoms of glaucoma. One of the side effects includes blindness. The last form of medicine used to treat glaucoma was released in 1996 and it was Pfizer’s Xalatan. These new sets of drugs not only work to alleviate patients of symptoms, but it also works to prove patient outcomes.
The article further discusses how a new pack of pharmaceutical companies are working to replace the oldies
Miguel, Maria Fernanda, ProfessorH. Kent Bowen. Ophthalmic Consultants of Boston and Dr. Bradford J. Shingleton. Harvard Business School. Rev. May 20, 1997.
Glaucoma is a disease of the eye and it is fluid pressure within the eye rises and if the eye is left untreated the patient might lose vision or maybe even blind. But this disease is generally affects both eyes but although one of their eyes may have more severe signs or symptoms then the other eye. When you have glaucoma there are small spaces in the front of the eye and they are called anterior chamber. There is clear liquid that flows in and out of the anterior chamber and the fluid nourishes and bathes nearby the tissues. And if the patient has glaucoma the fluid dose not drain like it should drain but the fluid drains out of the eye. And this may lead to fluid build up and pressure inside the rises of the eye. Unless the pressure is brought down and controlled and the optic nerves and some of the other parts of the eye might become damaged leading to ...
Vision loss from glaucoma is permanent but can be prevented with early detection and treatment. Since the symptoms of the disease are usually unnoticeable, regular eye examination are important especially for persons over the age of 35 and those in high risk group.
...ll help the company in selling generic drugs and provide affordable medications to its customer base.
16. Wang, Yadong. "An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration." Macromolecular Bioscience: 464-469. Web. 1 May 2014.
The last of these was the merger between Glaxo Wellcome and SmithKline Beecham, which formed the current company of GlaxoSmithKline. GlaxoSmithKline’s business is to discover effective medicines and healthcare products for people throughout the world and create shareholder value. They are one of the world’s leading producers of prescription medicines, vaccines and consumer healthcare products (Toiletries, Drinks). These products include SEROXAT/PAXIL, AUGMENTIN, WELLBUTRIN and ZOTRAN, all of which are pharmaceutical products. AQUAFRESH, LUCOZADE, NIQUITIN CQ and SENSODYNE, these are known as consumer healthcare products.
...emand for prescription drugs over the next 25 years. The number of people between 45 and 64 years old will increase 41% by 2015. Given the rise in age population and life expectancy rates around the world and the level of pharmaceutical use by aging individuals, growth in the industry should remain in an upward trend.
Imagine a researcher requesting you to copy a picture. It's a simple task. You move your instrument of illustration across a sheet of blank paper with ease, glancing from the given picture to your own sketch in progress. When you are finished you observe a satisfactory replica and feel a sense of accomplishment and proficiency with the similarity you have achieved between picture and sketch. Then the researcher queries whether you can tell him what you have drawn. You search the interconnected lines, the edges, and the shapes of your sketch but cannot answer what the picture represents. Finally, an explanation is given. You have just drawn a house- a simple triangle resting on top of a square. Your sense of accomplishment is quickly replaced with a feeling of despair.
They are missing out on opportunities that exist externally. It is time for the mindset of the company to evolve and understand that not all great ideas will be developed internally. In order to jump back to being the leading pharmaceutical company, they will have to open their doors to external pharmaceutical innovation.
McTigue Pierce, L. (2005, July). Pfizer: Growth amid adversity. Food & Drug Packaging, 69, p. 60.
Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has contributed great discoveries like the first cervical cancer vaccine and great resources like the Merck Manuals which are utilized as a source of information to doctors, scientists and consumers worldwide .
Ventola MS, C. L. (2011, November 11). The Drug Shortage Crisis in the United States. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278171/
A pharmaceutical company is the number of patients tested, to test their new drugs to fight cancer. Some marketing decisions, or fine-tune the new product ...
Robert, a 65 year-old male, has trouble reading fine detail, especially out of his central vision. He complains that his vision is blurred and that it is harder to see while operating a motor vehicle. In addition, sometimes objects appear wavy or crooked, which impairs his vision. His worst symptoms were that he occasionally lost the ability to distinguish between the features of familiar faces and he had a localized blind spot. Robert is not alone; many people suffer from symptoms related to loss and distortion of the visual field. He suffers from macular degeneration, the leading cause of decreased vision loss in the United States, especially for people over the age of 50 (Philippi, 2000).
For commodity generic drugs, Teva has an opportunity to expand its core business into emerging markets, but there it will have to face institutional voids because such markets are driven by physicians and both physician and other people are not aware about the effectiveness of generic drugs. To cope with the challenge of institutional voids Teva have to look for some competent small pharmaceutical firms for acquisition and some big firms for the joint venture. For changing the perceptions of people and physicians, Teva will require to run marketing campaigns and direct approaches to physicians to develop a market for their products.